{"abstract":"On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.","action":"Interim final rule; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/11/12/2026-23075.html","cfr_references":[{"chapter":null,"citation_url":null,"part":"1308","title":21}],"citation":"91 FR 72775","comment_url":"http://www.regulations.gov/commenton/DEA-2026-2080-0001","comments_close_on":"2026-12-14","correction_of":null,"corrections":[],"dates":"This rule is effective November 12, 2026. Comments must be submitted electronically or postmarked on or before December 14, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.","disposition_notes":null,"docket_ids":["Docket No. DEA-1775"],"dockets":[{"supporting_documents":[{"title":"Letter from HHS to DEA Oveporexton July2026","document_id":"DEA-2026-2080-0004"},{"title":"DEA 8FA Oveporexton Nov2026","document_id":"DEA-2026-2080-0003"},{"title":"HHS 8FA Oveporexton July2026","document_id":"DEA-2026-2080-0002"}],"agency_name":"DEA","documents":[{"comment_count":1,"comment_start_date":"2026-11-12","updated_at":"2026-11-19T00:56:51.645-05:00","comment_url":"https://www.regulations.gov/commenton/DEA-2026-2080-0001","allow_late_comments":false,"id":"DEA-2026-2080-0001","comment_end_date":"2026-12-15","regulations_dot_gov_open_for_comment":true}],"supporting_documents_count":3,"id":"DEA-2026-2080","title":"Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV (DEA1775)"}],"document_number":"2026-23075","effective_on":"2026-11-12","end_page":72781,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/11/12/2026-23075.xml","html_url":"https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-23075?publication_date=2026-11-12","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-11-12/2026-23075/mods.xml","not_received_for_publication":null,"page_length":7,"page_views":{"count":819,"last_updated":"2026-11-19 12:15:04 -0500"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-12/pdf/2026-23075.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-23075.pdf?1794258909","publication_date":"2026-11-12","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/11/12/2026-23075.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[{"title":"Letter from HHS to DEA Oveporexton July2026","document_id":"DEA-2026-2080-0004"},{"title":"DEA 8FA Oveporexton Nov2026","document_id":"DEA-2026-2080-0003"},{"title":"HHS 8FA Oveporexton July2026","document_id":"DEA-2026-2080-0002"}],"comments_count":1,"agency_id":"DEA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=DEA-2026-2080","supporting_documents_count":3,"docket_id":"DEA-2026-2080","document_id":"DEA-2026-2080-0001","regulation_id_number":null,"title":"Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV (DEA1775)","checked_regulationsdotgov_at":"2026-11-19T17:55:04Z"},"regulations_dot_gov_url":"http://www.regulations.gov/commenton/DEA-2026-2080-0001","significant":null,"signing_date":null,"start_page":72775,"subtype":null,"title":"Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV","toc_doc":"Placement of Oveporexton in Schedule IV","toc_subject":"Schedules of Controlled Substances","topics":["Administrative practice and procedure","Drug traffic control","Reporting and recordkeeping requirements"],"type":"Rule","volume":91}